Impact of the Spread of COVID-19 on the Economy, Medical Facilities and Overseas Projects
First written in FY2020. 7 of 15 entries say "Restated". Latest entry: FY2024.
The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.
- FY2024MitigatedAnnual report
「Although the impact of COVID-19 has been declining, the medical device industry is expected to continue fulfilling its social responsibility as an industry supporting healthcare professionals, in light of the challenges at medical facilities exposed by COVID-19.」
The Company indicated that the impact of COVID-19 on the business has been declining. At the same time, addressing challenges at medical facilities and fulfilling its social responsibility remain ongoing priorities. - FY2024-Q2RestatedAnnual report
「During the cumulative second-quarter period, no new business or other risks arose. In addition, there were no significant changes to the business and other risks described in the securities report for the previous fiscal year.」
The Company states that there are no new business or other risks and no material changes from the previous fiscal year. Disclosure of existing risks, including the potential impact depending on when COVID-19 comes under control and other factors, continues. - FY2024-Q1RestatedAnnual report
「There were no newly arising business or other risks during the cumulative first-quarter period. In addition, there were no material changes to the business or other risks described in the securities report for the previous fiscal year. The impact of the spread of COVID-19 on the Company's business and other matters may affect its financial position and operating results in the future, depending on when COVID-19 subsides and how other conditions develop.」
While stating that there are no new business or other risks or material changes to existing risks, the Company continues to disclose the potential impact on its financial position and operating results depending on when COVID-19 comes under control and other factors. - FY2023MitigatedAnnual report
「Although the impact of COVID-19 has been gradually declining,」
The Company indicated that the business impact of COVID-19 has been gradually declining. However, it continues to monitor challenges at medical facilities and the risk of a renewed spread of infection. - FY2023-Q3RestatedAnnual report
「There are no newly identified business or other risks during the cumulative third quarter period. There have also been no material changes to the business and other risks described in the annual securities report for the previous fiscal year. The impact of the spread of COVID-19 on the business may affect the Company's financial position and operating results in the future, depending on when COVID-19 comes under control and how other circumstances develop.」
While stating that there are no new business or other risks or material changes to existing risks, the Company continues to disclose the potential impact on its financial position and operating results depending on when COVID-19 comes under control and other factors. - FY2023-Q2RestatedAnnual report
「There are no newly identified business or other risks during the cumulative second quarter period. There have also been no material changes to the business and other risks described in the annual securities report for the previous fiscal year. The impact of the spread of COVID-19 on the business may affect the Company's financial position and operating results in the future, depending on when COVID-19 comes under control and how other circumstances develop.」
While stating that there are no new business or other risks or material changes to existing risks, the Company continues to disclose the potential impact on its financial position and operating results depending on when COVID-19 comes under control and other factors. - FY2023-Q1RestatedAnnual report
「There were no newly arising business or other risks during the cumulative first-quarter period. In addition, there were no material changes to the business or other risks described in the securities report for the previous fiscal year. The impact of the spread of COVID-19 on the Company's business and other matters may affect its financial position and operating results in the future, depending on when COVID-19 subsides and how other conditions develop.」
While stating that there are no new business or other risks or material changes to existing risks, the Company continues to disclose the potential impact on its financial position and operating results depending on when COVID-19 comes under control and other factors. - FY2022MitigatedAnnual report
「Although the impact of COVID-19 has been gradually declining, an early and complete resolution is not expected given the emergence of variants and other factors.」
While the impact of COVID-19 was described as gradually declining, the disclosure also noted the emergence of variants and the lack of prospects for an early and complete resolution. - FY2022-Q2RestatedAnnual report
「There are no newly identified business or other risks during the cumulative second quarter period. There have also been no material changes to the business and other risks described in the annual securities report for the previous fiscal year. The impact of the spread of COVID-19 on the business may affect the Company's financial position and operating results in the future, depending on when COVID-19 comes under control and how other circumstances develop.」
While stating that there are no new risks or material changes to existing risks, the Company continues to disclose the potential impact on its financial position and operating results depending on when COVID-19 comes under control and other factors. - FY2022-Q1RestatedAnnual report
「There were no newly arising business or other risks during the cumulative first-quarter period. In addition, there were no material changes to the business or other risks described in the securities report for the previous fiscal year. The impact of the spread of COVID-19 on the Company's business and other matters may affect its financial position and operating results in the future, depending on when COVID-19 subsides and how other conditions develop.」
While there are no new business or other risks and no material changes to existing risks, the Company continues to disclose the potential impact of the timing of the end of COVID-19 and other factors on its financial position and operating results. - FY2021MaterialisedAnnual report
「Domestic sales were ¥3,005.125 million, down 21.4% year on year, as major replacement projects had run their course by the previous fiscal year and the market entered a lull in replacement demand. In overseas markets, sales were ¥298.309 million, down 27.5% year on year, as many projects were forced to postpone sales due to delays in budget execution and other factors caused by the impact of COVID-19.」
The impact of COVID-19 actually emerged as delays in budget execution and postponed sales for overseas projects, and overseas sales of blood collection tube preparation equipment and systems decreased 27.5% year on year. - FY2021-Q3MaterialisedAnnual report
「Domestic sales were ¥1,372.014 million, down 45.3% from the same period of the previous year, as major replacement projects had run their course by the previous fiscal year and the market entered a lull in replacement demand. In overseas markets, sales were ¥263.415 million, down 10.7% from the same period of the previous year, as many projects were forced to delay sales due to the impact of COVID-19.」
The impact of COVID-19 actually emerged as delays in overseas sales projects, and overseas sales of blood collection tube preparation equipment and systems decreased 10.7% from the same period of the previous year. In Japan, sales of consumables also decreased 5.1% from the same period of the previous year due to declining outpatient visits and other factors. - FY2021-Q2MaterialisedAnnual report
「In the medical equipment industry as well, the outlook remains uncertain amid a marked deterioration in medical institutions' earnings caused by a decline in outpatient visits due to COVID-19 and the need to secure in-hospital systems that prioritize the COVID-19 response.」
The impact of COVID-19 has continued to emerge in the form of declining outpatient visits, changes to in-hospital systems and deteriorating earnings at medical institutions. - FY2021-Q1MaterialisedAnnual report
「The medical equipment industry has also been affected by a substantial deterioration in the operating conditions of medical institutions, as outpatient visits have declined and surgeries have been postponed because priority has been given to accepting and treating patients infected with COVID-19. The outlook therefore remains uncertain.」
The impact of COVID-19 has actually emerged in the medical industry as a decline in outpatient visits, postponed surgeries and deteriorating operating conditions at medical institutions. - FY2020MaterialisedAnnual report
「In overseas markets, sales were ¥411.353 million, down 29.3% year on year, due to the reaction to the concentration of sales projects for China in the previous fiscal year and delays in projects for China caused by the impact of COVID-19.」
The impact of COVID-19 resulted in actual delays in projects for China, and overseas sales of blood collection tube preparation equipment decreased 29.3% year on year.